PAVmed Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $PAVM in the last 30 days.
See all $PAVM insider activity →PAVmed Inc. (PAVM) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. Effective as of October 21, 2026, Lucid Diagnostics Inc. (the “ Lucid Diagnostics ”), a subsidiary of PAVmed Inc. (the “ Company ”), entered into subscription agreements (each, a “ Subscription Agreement ”) with certain accre
PAVmed Inc. (PAVM) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry Into a Material Definitive Agreement. On September 9, 2026, PAVmed Inc. (the “ Company ”) entered into a Sales Agreement (the “ Agreement ”) with A.G.P./Alliance Global Partners, as sales agent (the “ Agent ”), pursuant to which the Company may offer and sell, fr
PAVmed (PAVM) reported Q2 2026 GAAP net loss of $5.5M, non-GAAP adjusted loss of $1.7M, and revenue of $33K. Lucid Diagnostics revenue was $1.5M, driven by 2,770 EsoGuard tests. Cash balance was $3.8M. Veris Health aims for 1,000 patients in its registry. PortIO study showed 100% device patency, and FDA submission is targeted for early 2027. Octeris IRB approval is expected in October 2026. The company has $15M in senior secured notes maturing in 2029.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning PAVM (PAVmed Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent PAVM coverage spans earnings, corporate actions and financial news.
The new financing provides liquidity for Lucid Diagnostics and may improve the parent company's balance sheet.
Potential dilution and cash infusion for working capital.
Earnings miss and modest revenue highlight cash constraints, but progress on FDA submissions may support future upside.
Near-term catalysts center on FDA pathway acceptance for PortIO and submission timing for Veris, with liquidity tied to an EsoGuard LCD outcome.
The call adds a potential regulatory-timeline and capital-requirement catalyst for PortIO, alongside weak headline revenue and low cash.
AlphAI scores every news story that mentions PAVM with an AI model for sentiment and relevance, and aggregates insider trades from PAVmed Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
PAVmed Inc. (PAVM) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. Effective as of October 21, 2026, Lucid Diagnostics Inc. (the “ Lucid Diagnostics ”), a subsidiary of PAVmed Inc. (the “ Company ”), entered into subscription agreements (each, a “ Subscription Agreement ”) with certain accre
1 min readPAVmed Inc. (PAVM) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry Into a Material Definitive Agreement. On September 9, 2026, PAVmed Inc. (the “ Company ”) entered into a Sales Agreement (the “ Agreement ”) with A.G.P./Alliance Global Partners, as sales agent (the “ Agent ”), pursuant to which the Company may offer and sell, fr
1 min readPAVmed (PAVM) reported Q2 2026 GAAP net loss of $5.5M, non-GAAP adjusted loss of $1.7M, and revenue of $33K. Lucid Diagnostics revenue was $1.5M, driven by 2,770 EsoGuard tests. Cash balance was $3.8M. Veris Health aims for 1,000 patients in its registry. PortIO study showed 100% device patency, and FDA submission is targeted for early 2027. Octeris IRB approval is expected in October 2026. The company has $15M in senior secured notes maturing in 2029.
3 min readPAVmed reported Q2 2026 earnings call updates. Management said Veris is moving from pilot to full commercialization at Ohio State, with two-thirds of planned departments onboarded and a goal of 1,000 patient enrollments in year one. It plans early-2027 FDA 510(k) for Veris and a Q4 pre-submission for PortIO, citing first-in-human data.
4 min readPAVmed (PAVM) held its Q2 2026 earnings call. GAAP net loss was $5.5 million ($0.87/share) and non-GAAP adjusted loss was $1.7 million ($0.27/share). Revenue was $33,000, with pro forma income over $3 million. Cash was $3.8 million at June 30. Management discussed Veris, Lucid Diagnostics, and device regulatory timelines, including a targeted early-2027 510(k) submission for Veris.
6 min readPAVmed Inc. (PAVM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results Veris Health accelerated its commercial engagement with OSU-The James Veris Health implantable physiological monitor achieved development milestones towards upcoming FDA submission Luci
6 min readPAVmed Inc. (NASDAQ: PAVM) reported Q2 2026 results for the quarter ended June 30, 2026 and provided business updates across subsidiaries Lucid Diagnostics (NASDAQ: LUCD), Veris Health, and Octeris. Lucid recognized $1.5M EsoGuard revenue and processed 2,770 tests, and secured first lab benefit manager coverage. PAVmed cash was $3.8M; GAAP net loss was $5.5M ($0.87/share).
7 min readPAVmed Inc. (PAVM) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001624326 0001624326 2026-06-24 2026-06-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report
3 min readPAVmed Inc. (PAVM) is projected to report a loss of 70 cents per share in its upcoming earnings announcement. This information comes from a Refinitiv earnings preview. The article is very brief and provides no additional details.
1 min readPAVmed Inc. has registered 9,230,786 shares of common stock for resale by existing stockholders, including shares issued from the conversion of Series D preferred stock and shares issuable from related warrants. The company will not receive proceeds from these resales, but could receive up to $30 million if the warrants are exercised. This registration allows selling stockholders to sell shares on public markets, subject to various market conditions and limitations.
2 min read
